Critical	O
role	O
for	O
glucagon	B:C0061355
-	I:C0061355
like	I:C0061355
peptide	I:C0061355
-	I:C0061355
1	I:C0061355
in	O
symptomatic	O
post	O
-	I:C0020615
bariatric	I:C0020615
hypoglycaemia	I:C0020615
.	O

Critical	O
role	O
for	O
glucagon	O
-	I:C0061355
like	I:C0061355
peptide	I:C0061355
-	I:C0061355
1	I:C0061355
in	O
symptomatic	O
post	B:C0020615
-	I:C0020615
bariatric	I:C0020615
hypoglycaemia	I:C0020615
.	O

Post	B:C0020615
-	I:C0020615
bariatric	I:C0020615
hypoglycaemia	I:C0020615
(	O
Post	O
-	I:C0020615
bariatric	I:C0020615
hypoglycaemia	I:C0020615
)	O
is	O
a	O
rare	O
,	O
but	O
severe	O
,	O
metabolic	O
disorder	I:C0025517
arising	O
months	O
to	O
years	O
after	O
bariatric	O
surgery	I:C1456587
.	O

Post	O
-	I:C0020615
bariatric	I:C0020615
hypoglycaemia	I:C0020615
(	O
Post	B:C0020615
-	I:C0020615
bariatric	I:C0020615
hypoglycaemia	I:C0020615
)	O
is	O
a	O
rare	O
,	O
but	O
severe	O
,	O
metabolic	O
disorder	I:C0025517
arising	O
months	O
to	O
years	O
after	O
bariatric	O
surgery	I:C1456587
.	O

Post	O
-	I:C0020615
bariatric	I:C0020615
hypoglycaemia	I:C0020615
(	O
Post	O
-	I:C0020615
bariatric	I:C0020615
hypoglycaemia	I:C0020615
)	O
is	O
a	O
rare	O
,	O
but	O
severe	O
,	O
metabolic	B:C0025517
disorder	I:C0025517
arising	O
months	O
to	O
years	O
after	O
bariatric	O
surgery	I:C1456587
.	O

Post	O
-	I:C0020615
bariatric	I:C0020615
hypoglycaemia	I:C0020615
(	O
Post	O
-	I:C0020615
bariatric	I:C0020615
hypoglycaemia	I:C0020615
)	O
is	O
a	O
rare	O
,	O
but	O
severe	O
,	O
metabolic	O
disorder	I:C0025517
arising	O
months	O
to	O
years	O
after	O
bariatric	B:C1456587
surgery	I:C1456587
.	O

It	O
is	O
characterised	O
by	O
symptomatic	O
postprandial	O
hypoglycaemia	B:C0020615
,	O
with	O
inappropriately	O
elevated	O
insulin	O
concentrations	O
.	O

It	O
is	O
characterised	O
by	O
symptomatic	O
postprandial	O
hypoglycaemia	O
,	O
with	O
inappropriately	O
elevated	O
insulin	B:C0021641
concentrations	O
.	O

The	O
relative	O
contribution	O
of	O
exaggerated	O
incretin	B:C1562292
hormone	I:C1562292
signalling	O
to	O
dysregulated	O
insulin	O
secretion	I:C1256369
and	O
symptomatic	O
hypoglycaemia	O
is	O
a	O
subject	O
of	O
ongoing	O
inquiry	O
.	O

The	O
relative	O
contribution	O
of	O
exaggerated	O
incretin	O
hormone	I:C1562292
signalling	B:C3537152
to	O
dysregulated	O
insulin	O
secretion	I:C1256369
and	O
symptomatic	O
hypoglycaemia	O
is	O
a	O
subject	O
of	O
ongoing	O
inquiry	O
.	O

The	O
relative	O
contribution	O
of	O
exaggerated	O
incretin	O
hormone	I:C1562292
signalling	O
to	O
dysregulated	O
insulin	B:C1256369
secretion	I:C1256369
and	O
symptomatic	O
hypoglycaemia	O
is	O
a	O
subject	O
of	O
ongoing	O
inquiry	O
.	O

The	O
relative	O
contribution	O
of	O
exaggerated	O
incretin	O
hormone	I:C1562292
signalling	O
to	O
dysregulated	O
insulin	O
secretion	I:C1256369
and	O
symptomatic	O
hypoglycaemia	B:C0020615
is	O
a	O
subject	O
of	O
ongoing	O
inquiry	O
.	O

This	O
study	B:C2603343
was	O
designed	O
to	O
test	O
the	O
hypothesis	O
that	O
Post	O
-	I:C0020615
bariatric	I:C0020615
hypoglycaemia	I:C0020615
and	O
associated	O
symptoms	O
are	O
primarily	O
mediated	O
by	O
glucagon	O
-	I:C0061355
like	I:C0061355
peptide	I:C0061355
-	I:C0061355
1	I:C0061355
(	O
glucagon	O
-	I:C0061355
like	I:C0061355
peptide	I:C0061355
-	I:C0061355
1	I:C0061355
)	O
.	O

This	O
study	O
was	O
designed	O
to	O
test	O
the	O
hypothesis	O
that	O
Post	B:C0020615
-	I:C0020615
bariatric	I:C0020615
hypoglycaemia	I:C0020615
and	O
associated	O
symptoms	O
are	O
primarily	O
mediated	O
by	O
glucagon	O
-	I:C0061355
like	I:C0061355
peptide	I:C0061355
-	I:C0061355
1	I:C0061355
(	O
glucagon	O
-	I:C0061355
like	I:C0061355
peptide	I:C0061355
-	I:C0061355
1	I:C0061355
)	O
.	O

This	O
study	O
was	O
designed	O
to	O
test	O
the	O
hypothesis	O
that	O
Post	O
-	I:C0020615
bariatric	I:C0020615
hypoglycaemia	I:C0020615
and	O
associated	O
symptoms	B:C1457887
are	O
primarily	O
mediated	O
by	O
glucagon	O
-	I:C0061355
like	I:C0061355
peptide	I:C0061355
-	I:C0061355
1	I:C0061355
(	O
glucagon	O
-	I:C0061355
like	I:C0061355
peptide	I:C0061355
-	I:C0061355
1	I:C0061355
)	O
.	O

This	O
study	O
was	O
designed	O
to	O
test	O
the	O
hypothesis	O
that	O
Post	O
-	I:C0020615
bariatric	I:C0020615
hypoglycaemia	I:C0020615
and	O
associated	O
symptoms	O
are	O
primarily	O
mediated	O
by	O
glucagon	B:C0061355
-	I:C0061355
like	I:C0061355
peptide	I:C0061355
-	I:C0061355
1	I:C0061355
(	O
glucagon	O
-	I:C0061355
like	I:C0061355
peptide	I:C0061355
-	I:C0061355
1	I:C0061355
)	O
.	O

This	O
study	O
was	O
designed	O
to	O
test	O
the	O
hypothesis	O
that	O
Post	O
-	I:C0020615
bariatric	I:C0020615
hypoglycaemia	I:C0020615
and	O
associated	O
symptoms	O
are	O
primarily	O
mediated	O
by	O
glucagon	O
-	I:C0061355
like	I:C0061355
peptide	I:C0061355
-	I:C0061355
1	I:C0061355
(	O
glucagon	B:C0061355
-	I:C0061355
like	I:C0061355
peptide	I:C0061355
-	I:C0061355
1	I:C0061355
)	O
.	O

We	O
conducted	O
a	O
double	B:C0013072
-	I:C0013072
blinded	I:C0013072
crossover	O
study	I:C0150097
wherein	O
eight	O
participants	O
with	O
confirmed	O
Post	O
-	I:C0020615
bariatric	I:C0020615
hypoglycaemia	I:C0020615
were	O
assigned	O
in	O
random	O
order	O
to	O
intravenous	O
infusion	I:C0021440
of	O
the	O
GLP	O
-	I:C0378073
1	I:C0378073
receptor	I:C0378073
(	O
GLP	O
-	I:C0378073
1	I:C0378073
receptor	I:C0378073
)	O
antagonist	O
.	O

We	O
conducted	O
a	O
double	O
-	I:C0013072
blinded	I:C0013072
crossover	B:C0150097
study	I:C0150097
wherein	O
eight	O
participants	O
with	O
confirmed	O
Post	O
-	I:C0020615
bariatric	I:C0020615
hypoglycaemia	I:C0020615
were	O
assigned	O
in	O
random	O
order	O
to	O
intravenous	O
infusion	I:C0021440
of	O
the	O
GLP	O
-	I:C0378073
1	I:C0378073
receptor	I:C0378073
(	O
GLP	O
-	I:C0378073
1	I:C0378073
receptor	I:C0378073
)	O
antagonist	O
.	O

We	O
conducted	O
a	O
double	O
-	I:C0013072
blinded	I:C0013072
crossover	O
study	I:C0150097
wherein	O
eight	O
participants	B:C0679646
with	O
confirmed	O
Post	O
-	I:C0020615
bariatric	I:C0020615
hypoglycaemia	I:C0020615
were	O
assigned	O
in	O
random	O
order	O
to	O
intravenous	O
infusion	I:C0021440
of	O
the	O
GLP	O
-	I:C0378073
1	I:C0378073
receptor	I:C0378073
(	O
GLP	O
-	I:C0378073
1	I:C0378073
receptor	I:C0378073
)	O
antagonist	O
.	O

We	O
conducted	O
a	O
double	O
-	I:C0013072
blinded	I:C0013072
crossover	O
study	I:C0150097
wherein	O
eight	O
participants	O
with	O
confirmed	O
Post	B:C0020615
-	I:C0020615
bariatric	I:C0020615
hypoglycaemia	I:C0020615
were	O
assigned	O
in	O
random	O
order	O
to	O
intravenous	O
infusion	I:C0021440
of	O
the	O
GLP	O
-	I:C0378073
1	I:C0378073
receptor	I:C0378073
(	O
GLP	O
-	I:C0378073
1	I:C0378073
receptor	I:C0378073
)	O
antagonist	O
.	O

We	O
conducted	O
a	O
double	O
-	I:C0013072
blinded	I:C0013072
crossover	O
study	I:C0150097
wherein	O
eight	O
participants	O
with	O
confirmed	O
Post	O
-	I:C0020615
bariatric	I:C0020615
hypoglycaemia	I:C0020615
were	O
assigned	O
in	O
random	O
order	O
to	O
intravenous	B:C0021440
infusion	I:C0021440
of	O
the	O
GLP	O
-	I:C0378073
1	I:C0378073
receptor	I:C0378073
(	O
GLP	O
-	I:C0378073
1	I:C0378073
receptor	I:C0378073
)	O
antagonist	O
.	O

We	O
conducted	O
a	O
double	O
-	I:C0013072
blinded	I:C0013072
crossover	O
study	I:C0150097
wherein	O
eight	O
participants	O
with	O
confirmed	O
Post	O
-	I:C0020615
bariatric	I:C0020615
hypoglycaemia	I:C0020615
were	O
assigned	O
in	O
random	O
order	O
to	O
intravenous	O
infusion	I:C0021440
of	O
the	O
GLP	B:C0378073
-	I:C0378073
1	I:C0378073
receptor	I:C0378073
(	O
GLP	O
-	I:C0378073
1	I:C0378073
receptor	I:C0378073
)	O
antagonist	O
.	O

We	O
conducted	O
a	O
double	O
-	I:C0013072
blinded	I:C0013072
crossover	O
study	I:C0150097
wherein	O
eight	O
participants	O
with	O
confirmed	O
Post	O
-	I:C0020615
bariatric	I:C0020615
hypoglycaemia	I:C0020615
were	O
assigned	O
in	O
random	O
order	O
to	O
intravenous	O
infusion	I:C0021440
of	O
the	O
GLP	O
-	I:C0378073
1	I:C0378073
receptor	I:C0378073
(	O
GLP	B:C0378073
-	I:C0378073
1	I:C0378073
receptor	I:C0378073
)	O
antagonist	O
.	O

We	O
conducted	O
a	O
double	O
-	I:C0013072
blinded	I:C0013072
crossover	O
study	I:C0150097
wherein	O
eight	O
participants	O
with	O
confirmed	O
Post	O
-	I:C0020615
bariatric	I:C0020615
hypoglycaemia	I:C0020615
were	O
assigned	O
in	O
random	O
order	O
to	O
intravenous	O
infusion	I:C0021440
of	O
the	O
GLP	O
-	I:C0378073
1	I:C0378073
receptor	I:C0378073
(	O
GLP	O
-	I:C0378073
1	I:C0378073
receptor	I:C0378073
)	O
antagonist	B:C0003139
.	O

Exendin	B:C0247947
(	I:C0247947
9	I:C0247947
-	I:C0247947
39	I:C0247947
)	I:C0247947
(	O
Ex	O
-	I:C0247947
9	I:C0247947
)	O
,	O
or	O
placebo	O
during	O
an	O
OGTT	O
on	O
two	O
separate	O
days	O
at	O
the	O
Stanford	O
University	I:C0041740
Clinical	O
and	I:C1274109
Translational	I:C1274109
Research	I:C1274109
Unit	I:C1274109
.	O

Exendin	O
(	I:C0247947
9	I:C0247947
-	I:C0247947
39	I:C0247947
)	I:C0247947
(	O
Ex	B:C0247947
-	I:C0247947
9	I:C0247947
)	O
,	O
or	O
placebo	O
during	O
an	O
OGTT	O
on	O
two	O
separate	O
days	O
at	O
the	O
Stanford	O
University	I:C0041740
Clinical	O
and	I:C1274109
Translational	I:C1274109
Research	I:C1274109
Unit	I:C1274109
.	O

Exendin	O
(	I:C0247947
9	I:C0247947
-	I:C0247947
39	I:C0247947
)	I:C0247947
(	O
Ex	O
-	I:C0247947
9	I:C0247947
)	O
,	O
or	O
placebo	B:C0032042
during	O
an	O
OGTT	O
on	O
two	O
separate	O
days	O
at	O
the	O
Stanford	O
University	I:C0041740
Clinical	O
and	I:C1274109
Translational	I:C1274109
Research	I:C1274109
Unit	I:C1274109
.	O

Exendin	O
(	I:C0247947
9	I:C0247947
-	I:C0247947
39	I:C0247947
)	I:C0247947
(	O
Ex	O
-	I:C0247947
9	I:C0247947
)	O
,	O
or	O
placebo	O
during	O
an	O
OGTT	B:C0029161
on	O
two	O
separate	O
days	O
at	O
the	O
Stanford	O
University	I:C0041740
Clinical	O
and	I:C1274109
Translational	I:C1274109
Research	I:C1274109
Unit	I:C1274109
.	O

Exendin	O
(	I:C0247947
9	I:C0247947
-	I:C0247947
39	I:C0247947
)	I:C0247947
(	O
Ex	O
-	I:C0247947
9	I:C0247947
)	O
,	O
or	O
placebo	O
during	O
an	O
OGTT	O
on	O
two	O
separate	O
days	O
at	O
the	O
Stanford	B:C0041740
University	I:C0041740
Clinical	O
and	I:C1274109
Translational	I:C1274109
Research	I:C1274109
Unit	I:C1274109
.	O

Exendin	O
(	I:C0247947
9	I:C0247947
-	I:C0247947
39	I:C0247947
)	I:C0247947
(	O
Ex	O
-	I:C0247947
9	I:C0247947
)	O
,	O
or	O
placebo	O
during	O
an	O
OGTT	O
on	O
two	O
separate	O
days	O
at	O
the	O
Stanford	O
University	I:C0041740
Clinical	B:C1274109
and	I:C1274109
Translational	I:C1274109
Research	I:C1274109
Unit	I:C1274109
.	O

Results	O
were	O
compared	O
with	O
a	O
cohort	B:C0599755
of	O
BMI	O
-	O
and	O
glucose	O
-	O
matched	O
non-surgical	O
controls	O
(	O
NSCs	O
)	O
.	O

Results	O
were	O
compared	O
with	O
a	O
cohort	O
of	O
BMI	B:C1305855
-	O
and	O
glucose	O
-	O
matched	O
non-surgical	O
controls	O
(	O
NSCs	O
)	O
.	O

Results	O
were	O
compared	O
with	O
a	O
cohort	O
of	O
BMI	O
-	O
and	O
glucose	B:C0017725
-	O
matched	O
non-surgical	O
controls	O
(	O
NSCs	O
)	O
.	O

Infusion	B:C0574032
of	O
Ex	O
-	I:C0247947
9	I:C0247947
decreased	O
the	O
time	O
to	O
peak	O
glucose	O
and	O
rate	O
of	O
glucose	O
decline	O
during	O
OGTT	O
,	O
and	O
raised	O
the	O
postprandial	O
nadir	O
by	O
over	O
70	O
%	O
,	O
normalising	O
it	O
relative	O
to	O
NSCs	O
and	O
preventing	O
hypoglycaemia	O
in	O
all	O
Post	O
-	I:C0020615
bariatric	I:C0020615
hypoglycaemia	I:C0020615
participants	O
.	O

Infusion	O
of	O
Ex	B:C0247947
-	I:C0247947
9	I:C0247947
decreased	O
the	O
time	O
to	O
peak	O
glucose	O
and	O
rate	O
of	O
glucose	O
decline	O
during	O
OGTT	O
,	O
and	O
raised	O
the	O
postprandial	O
nadir	O
by	O
over	O
70	O
%	O
,	O
normalising	O
it	O
relative	O
to	O
NSCs	O
and	O
preventing	O
hypoglycaemia	O
in	O
all	O
Post	O
-	I:C0020615
bariatric	I:C0020615
hypoglycaemia	I:C0020615
participants	O
.	O

Infusion	O
of	O
Ex	O
-	I:C0247947
9	I:C0247947
decreased	O
the	O
time	O
to	O
peak	O
glucose	B:C0017725
and	O
rate	O
of	O
glucose	O
decline	O
during	O
OGTT	O
,	O
and	O
raised	O
the	O
postprandial	O
nadir	O
by	O
over	O
70	O
%	O
,	O
normalising	O
it	O
relative	O
to	O
NSCs	O
and	O
preventing	O
hypoglycaemia	O
in	O
all	O
Post	O
-	I:C0020615
bariatric	I:C0020615
hypoglycaemia	I:C0020615
participants	O
.	O

Infusion	O
of	O
Ex	O
-	I:C0247947
9	I:C0247947
decreased	O
the	O
time	O
to	O
peak	O
glucose	O
and	O
rate	O
of	O
glucose	B:C0017725
decline	O
during	O
OGTT	O
,	O
and	O
raised	O
the	O
postprandial	O
nadir	O
by	O
over	O
70	O
%	O
,	O
normalising	O
it	O
relative	O
to	O
NSCs	O
and	O
preventing	O
hypoglycaemia	O
in	O
all	O
Post	O
-	I:C0020615
bariatric	I:C0020615
hypoglycaemia	I:C0020615
participants	O
.	O

Infusion	O
of	O
Ex	O
-	I:C0247947
9	I:C0247947
decreased	O
the	O
time	O
to	O
peak	O
glucose	O
and	O
rate	O
of	O
glucose	O
decline	O
during	O
OGTT	B:C0029161
,	O
and	O
raised	O
the	O
postprandial	O
nadir	O
by	O
over	O
70	O
%	O
,	O
normalising	O
it	O
relative	O
to	O
NSCs	O
and	O
preventing	O
hypoglycaemia	O
in	O
all	O
Post	O
-	I:C0020615
bariatric	I:C0020615
hypoglycaemia	I:C0020615
participants	O
.	O

Infusion	O
of	O
Ex	O
-	I:C0247947
9	I:C0247947
decreased	O
the	O
time	O
to	O
peak	O
glucose	O
and	O
rate	O
of	O
glucose	O
decline	O
during	O
OGTT	O
,	O
and	O
raised	O
the	O
postprandial	O
nadir	O
by	O
over	O
70	O
%	O
,	O
normalising	O
it	O
relative	O
to	O
NSCs	O
and	O
preventing	O
hypoglycaemia	B:C0020615
in	O
all	O
Post	O
-	I:C0020615
bariatric	I:C0020615
hypoglycaemia	I:C0020615
participants	O
.	O

Infusion	O
of	O
Ex	O
-	I:C0247947
9	I:C0247947
decreased	O
the	O
time	O
to	O
peak	O
glucose	O
and	O
rate	O
of	O
glucose	O
decline	O
during	O
OGTT	O
,	O
and	O
raised	O
the	O
postprandial	O
nadir	O
by	O
over	O
70	O
%	O
,	O
normalising	O
it	O
relative	O
to	O
NSCs	O
and	O
preventing	O
hypoglycaemia	O
in	O
all	O
Post	B:C0020615
-	I:C0020615
bariatric	I:C0020615
hypoglycaemia	I:C0020615
participants	O
.	O

Infusion	O
of	O
Ex	O
-	I:C0247947
9	I:C0247947
decreased	O
the	O
time	O
to	O
peak	O
glucose	O
and	O
rate	O
of	O
glucose	O
decline	O
during	O
OGTT	O
,	O
and	O
raised	O
the	O
postprandial	O
nadir	O
by	O
over	O
70	O
%	O
,	O
normalising	O
it	O
relative	O
to	O
NSCs	O
and	O
preventing	O
hypoglycaemia	O
in	O
all	O
Post	O
-	I:C0020615
bariatric	I:C0020615
hypoglycaemia	I:C0020615
participants	B:C0679646
.	O

Insulin	B:C0021641
AUC	O
and	O
secretion	O
rate	O
decreased	O
by	O
57	O
%	O
and	O
71	O
%	O
respectively	O
,	O
and	O
peak	O
postprandial	O
insulin	O
was	O
normalised	O
relative	O
to	O
NSCs	O
.	O

Insulin	O
AUC	O
and	O
secretion	B:C0312431
rate	O
decreased	O
by	O
57	O
%	O
and	O
71	O
%	O
respectively	O
,	O
and	O
peak	O
postprandial	O
insulin	O
was	O
normalised	O
relative	O
to	O
NSCs	O
.	O

Insulin	O
AUC	O
and	O
secretion	O
rate	O
decreased	O
by	O
57	O
%	O
and	O
71	O
%	O
respectively	O
,	O
and	O
peak	O
postprandial	O
insulin	B:C0021641
was	O
normalised	O
relative	O
to	O
NSCs	O
.	O

Autonomic	B:C2674101
and	O
neuroglycopenic	O
symptoms	I:C1457887
were	O
significantly	O
reduced	O
during	O
Ex	O
-	I:C0247947
9	I:C0247947
infusion	O
.	O

Autonomic	O
and	O
neuroglycopenic	B:C1457887
symptoms	I:C1457887
were	O
significantly	O
reduced	O
during	O
Ex	O
-	I:C0247947
9	I:C0247947
infusion	O
.	O

Autonomic	O
and	O
neuroglycopenic	O
symptoms	I:C1457887
were	O
significantly	O
reduced	O
during	O
Ex	B:C0247947
-	I:C0247947
9	I:C0247947
infusion	O
.	O

Autonomic	O
and	O
neuroglycopenic	O
symptoms	I:C1457887
were	O
significantly	O
reduced	O
during	O
Ex	O
-	I:C0247947
9	I:C0247947
infusion	B:C0574032
.	O

GLP	B:C0378073
-	I:C0378073
1	I:C0378073
receptor	I:C0378073
blockade	O
prevented	O
hypoglycaemia	O
in	O
100	O
%	O
of	O
individuals	O
,	O
normalised	O
beta	O
cell	I:C0007613
function	I:C0007613
and	O
reversed	O
neuroglycopenic	I:C1457887
symptoms	I:C1457887
,	O
supporting	O
the	O
conclusion	O
that	O
glucagon	O
-	I:C0061355
like	I:C0061355
peptide	I:C0061355
-	I:C0061355
1	I:C0061355
plays	O
a	O
primary	O
role	O
in	O
mediating	O
hyperinsulinaemic	O
hypoglycaemia	I:C1864903
in	O
Post	O
-	I:C0020615
bariatric	I:C0020615
hypoglycaemia	I:C0020615
.	O

GLP	O
-	I:C0378073
1	I:C0378073
receptor	I:C0378073
blockade	O
prevented	O
hypoglycaemia	B:C0020615
in	O
100	O
%	O
of	O
individuals	O
,	O
normalised	O
beta	O
cell	I:C0007613
function	I:C0007613
and	O
reversed	O
neuroglycopenic	I:C1457887
symptoms	I:C1457887
,	O
supporting	O
the	O
conclusion	O
that	O
glucagon	O
-	I:C0061355
like	I:C0061355
peptide	I:C0061355
-	I:C0061355
1	I:C0061355
plays	O
a	O
primary	O
role	O
in	O
mediating	O
hyperinsulinaemic	O
hypoglycaemia	I:C1864903
in	O
Post	O
-	I:C0020615
bariatric	I:C0020615
hypoglycaemia	I:C0020615
.	O

GLP	O
-	I:C0378073
1	I:C0378073
receptor	I:C0378073
blockade	O
prevented	O
hypoglycaemia	O
in	O
100	O
%	O
of	O
individuals	B:C0237401
,	O
normalised	O
beta	O
cell	I:C0007613
function	I:C0007613
and	O
reversed	O
neuroglycopenic	I:C1457887
symptoms	I:C1457887
,	O
supporting	O
the	O
conclusion	O
that	O
glucagon	O
-	I:C0061355
like	I:C0061355
peptide	I:C0061355
-	I:C0061355
1	I:C0061355
plays	O
a	O
primary	O
role	O
in	O
mediating	O
hyperinsulinaemic	O
hypoglycaemia	I:C1864903
in	O
Post	O
-	I:C0020615
bariatric	I:C0020615
hypoglycaemia	I:C0020615
.	O

GLP	O
-	I:C0378073
1	I:C0378073
receptor	I:C0378073
blockade	O
prevented	O
hypoglycaemia	O
in	O
100	O
%	O
of	O
individuals	O
,	O
normalised	O
beta	B:C0007613
cell	I:C0007613
function	I:C0007613
and	O
reversed	O
neuroglycopenic	I:C1457887
symptoms	I:C1457887
,	O
supporting	O
the	O
conclusion	O
that	O
glucagon	O
-	I:C0061355
like	I:C0061355
peptide	I:C0061355
-	I:C0061355
1	I:C0061355
plays	O
a	O
primary	O
role	O
in	O
mediating	O
hyperinsulinaemic	O
hypoglycaemia	I:C1864903
in	O
Post	O
-	I:C0020615
bariatric	I:C0020615
hypoglycaemia	I:C0020615
.	O

GLP	O
-	I:C0378073
1	I:C0378073
receptor	I:C0378073
blockade	O
prevented	O
hypoglycaemia	O
in	O
100	O
%	O
of	O
individuals	O
,	O
normalised	O
beta	O
cell	I:C0007613
function	I:C0007613
and	O
reversed	B:C1457887
neuroglycopenic	I:C1457887
symptoms	I:C1457887
,	O
supporting	O
the	O
conclusion	O
that	O
glucagon	O
-	I:C0061355
like	I:C0061355
peptide	I:C0061355
-	I:C0061355
1	I:C0061355
plays	O
a	O
primary	O
role	O
in	O
mediating	O
hyperinsulinaemic	O
hypoglycaemia	I:C1864903
in	O
Post	O
-	I:C0020615
bariatric	I:C0020615
hypoglycaemia	I:C0020615
.	O

GLP	O
-	I:C0378073
1	I:C0378073
receptor	I:C0378073
blockade	O
prevented	O
hypoglycaemia	O
in	O
100	O
%	O
of	O
individuals	O
,	O
normalised	O
beta	O
cell	I:C0007613
function	I:C0007613
and	O
reversed	O
neuroglycopenic	I:C1457887
symptoms	I:C1457887
,	O
supporting	O
the	O
conclusion	O
that	O
glucagon	B:C0061355
-	I:C0061355
like	I:C0061355
peptide	I:C0061355
-	I:C0061355
1	I:C0061355
plays	O
a	O
primary	O
role	O
in	O
mediating	O
hyperinsulinaemic	O
hypoglycaemia	I:C1864903
in	O
Post	O
-	I:C0020615
bariatric	I:C0020615
hypoglycaemia	I:C0020615
.	O

GLP	O
-	I:C0378073
1	I:C0378073
receptor	I:C0378073
blockade	O
prevented	O
hypoglycaemia	O
in	O
100	O
%	O
of	O
individuals	O
,	O
normalised	O
beta	O
cell	I:C0007613
function	I:C0007613
and	O
reversed	O
neuroglycopenic	I:C1457887
symptoms	I:C1457887
,	O
supporting	O
the	O
conclusion	O
that	O
glucagon	O
-	I:C0061355
like	I:C0061355
peptide	I:C0061355
-	I:C0061355
1	I:C0061355
plays	O
a	O
primary	O
role	O
in	O
mediating	O
hyperinsulinaemic	B:C1864903
hypoglycaemia	I:C1864903
in	O
Post	O
-	I:C0020615
bariatric	I:C0020615
hypoglycaemia	I:C0020615
.	O

GLP	O
-	I:C0378073
1	I:C0378073
receptor	I:C0378073
blockade	O
prevented	O
hypoglycaemia	O
in	O
100	O
%	O
of	O
individuals	O
,	O
normalised	O
beta	O
cell	I:C0007613
function	I:C0007613
and	O
reversed	O
neuroglycopenic	I:C1457887
symptoms	I:C1457887
,	O
supporting	O
the	O
conclusion	O
that	O
glucagon	O
-	I:C0061355
like	I:C0061355
peptide	I:C0061355
-	I:C0061355
1	I:C0061355
plays	O
a	O
primary	O
role	O
in	O
mediating	O
hyperinsulinaemic	O
hypoglycaemia	I:C1864903
in	O
Post	B:C0020615
-	I:C0020615
bariatric	I:C0020615
hypoglycaemia	I:C0020615
.	O

Competitive	O
antagonism	B:C0013159
at	O
the	O
GLP	O
-	I:C0378073
1	I:C0378073
receptor	I:C0378073
merits	O
consideration	O
as	O
a	O
therapeutic	O
strategy	O
.	O

Competitive	O
antagonism	O
at	O
the	O
GLP	B:C0378073
-	I:C0378073
1	I:C0378073
receptor	I:C0378073
merits	O
consideration	O
as	O
a	O
therapeutic	O
strategy	O
.	O

